High in vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrug-resistant Neisseria gonorrhoeae isolates suggests a new effective option for oral treatment of gonorrhea

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 9, 2014, Pages 5585-5588

  Jacobsson, Susanne ^a   Golparian, Daniel ^a   Alm, Richard A ^b   Huband, Michael ^b   Mueller, John ^b   Jensen, Jorgen Skov ^c   Ohnishi, Makoto ^d   Unemo, Magnus ^a  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^b ASTRAZENECA   (United Kingdom)

^c STATENS SERUM INSTITUT   (Denmark)

^d NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; AZD 0914; AZITHROMYCIN; CEFIXIME; CEFTRIAXONE; CIPROFLOXACIN; GYRASE INHIBITOR; SPECTINOMYCIN; TETRACYCLINE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BARBITURIC ACID DERIVATIVE; DNA TOPOISOMERASE (ATP HYDROLYSING); SPIRO COMPOUND; ZOLIFLODACIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; DRUG DETERMINATION; DRUG SCREENING; GONORRHEA; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NEISSERIA GONORRHOEAE; NONHUMAN; PRIORITY JOURNAL; DRUG EFFECTS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; BARBITURATES; DNA GYRASE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GONORRHEA; MICROBIAL SENSITIVITY TESTS; NEISSERIA GONORRHOEAE; SPIRO COMPOUNDS; TOPOISOMERASE II INHIBITORS;

EID: 84906090956     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03090-14     Document Type: Article

References (34)

1. World Health Organization. 2012. Global incidence and prevalence of selected curable sexually transmitted infections - 2008. World Health Organization, Geneva, Switzerland.
2. Unemo M, Nicholas RA. 2012. Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea. Future Microbiol. 7:1401-1422. http://dx.doi.org/10.2217/fmb.12.117.
3. Tapsall JW, Ndowa F, Lewis DA, Unemo M. 2009. Meeting the public health challenge of multidrug- and extensively drug-resistant Neisseria gonorrhoeae. Expert Rev. Anti Infect. Ther. 7:821-834. http://dx.doi.org/10.1586/eri.09.63.
4. Unemo M, Shafer WM. 2011. Antibiotic resistance in Neisseria gonorrhoeae: origin, evolution, and lessons learned for the future. Ann. N. Y. Acad. Sci. 1230:E19-E28. http://dx.doi.org/10.1111/j.1749-6632.2011.06215.x.
5. Lewis DA. 2010. The gonococcus fights back: is this time a knock out? Sex. Transm. Infect. 86:415-421. http://dx.doi.org/10.1136/sti.2010.042648.
6. Allen VG, Mitterni L, Seah C, Rebbapragada A, Martin IE, Lee C, Siebert H, Towns L, Melano RG, Low DE. 2013. Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. JAMA 309:163-170. http://dx.doi.org/10.1001/jama.2012.176575.
7. Ison CA, Hussey J, Sankar KN, Evans J, Alexander S. 2011. Gonorrhoea treatment failures to cefixime and azithromycin in England. Euro Surveill. 16:19833.
8. Lewis DA, Sriruttan C, Müller EE, Golparian D, Gumede L, Fick D, de Wet J, Maseko V, Coetzee J, Unemo M. 2013. Phenotypic and genetic characterization of the first two cases of extended-spectrum cephalosporin resistant Neisseria gonorrhoeae infection in South Africa and association with cefixime treatment failure. J. Antimicrob. Chemother. 68:1267-1270. http://dx.doi.org/10.1093/jac/dkt034.
9. Unemo M, Golparian D, Nicholas R, Ohnishi M, Gallay A, Sednaoui P. 2012. High-level cefixime- and ceftriaxone-resistant N. gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob. Agents Chemother. 56:1273-1280. http://dx.doi.org/10.1128/AAC. 05760-11.
10. Unemo M, Golparian D, Stary A, Eigentler A. 2011. First Neisseria gonorrhoeae strain with resistance to cefixime causing gonorrhoea treatment failure in Austria, 2011. Euro Surveill. 16:19998.
11. Unemo M, Golparian D, Syversen G, Vestrheim DF, Moi M. 2010. Two cases of verified clinical failures using internationally recommended firstline cefixime for gonorrhoea treatment, Norway, 2010. Euro Surveill. 15:19721.
12. Yokoi S, Deguchi T, Ozawa T, Yasuda M, Ito S, Kubota Y, Tamaki M, Maeda S. 2007. Threat to cefixime treatment for gonorrhea. Emerg. Infect. Dis. 13:1275-1277.
13. Ohnishi M, Golparian D, Shimuta K, Saika T, Hoshina S, Iwasaku K, Nakayama S, Kitawaki J, Unemo M. 2011. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea? Detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob. Agents Chemother. 55:3538-3545. http://dx.doi.org/10.1128/AAC.00325-11.
14. Tapsall J, Read P, Carmody C, Bourne C, Ray S, Limnios A, Sloots T, Whiley D. 2009. Two cases of failed ceftriaxone treatment in pharyngeal gonorrhoea verified by molecular microbiological methods. J. Med. Microbiol. 58:683-687. http://dx.doi.org/10.1099/jmm.0.007641-0.
15. Unemo M, Golparian D, Hestner A. 2011. Ceftriaxone treatment failure of pharyngeal gonorrhoea verified by international recommendations, Sweden, July 2010. Euro Surveill. 16:1-3.
16. Unemo M, Golparian D, Potočnik M, Jeverica S. 2012. Treatment failure of pharyngeal gonorrhoea with internationally recommended first-line ceftriaxone verified in Slovenia, September 2011. Euro Surveill. 17: 1-4.
17. Read PJ, Limnios EA, McNulty A, Whiley D, Lahra LM. 2013. One confirmed and one suspected case of pharyngeal gonorrhoea treatment failure following 500 mg ceftriaxone in Sydney, Australia. Sex. Health 10:460-462. http://dx.doi.org/10.1071/SH13077.
18. Chen YM, Stevens K, Tideman R, Zaia A, Tomita T, Fairley CK, Lahra M, Whiley D, Hogg G. 2013. Failure of ceftriaxone 500 mg to eradicate pharyngeal gonorrhoea, Australia. J. Antimicrob. Chemother. 68:1445-1447. http://dx.doi.org/10.1093/jac/dkt017.
19. Cámara J, Serra J, Ayats J, Bastida T, Carnicer-Pont D, Andreu A, Ardanuy C. 2012. Molecular characterization of two high-level ceftriax-one-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain. J. Antimicrob. Chemother. 67:1858-1860. http://dx.doi.org/10.1093/jac/ dks162.
20. World Health Organization, Department of Reproductive Health and Research. 2012. Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae, p 1-36. World Health Organization, Geneva, Switzerland.
21. Centers for Disease Control and Prevention. 2012. Cephalosporin-resistant Neisseria gonorrhoeae public health response plan, p 1-43. Centers for Disease Control and Prevention, Atlanta, GA.
22. European Centre for Disease Prevention and Control. 2012. Response plan to control and manage the threat of multidrug-resistant gonorrhoea in Europe, p 1-23. European Centre for Disease Prevention and Control, Stockholm, Sweden.
23. Huband MD, Otterson LG, Doig PC, Giacobbe RA, Patey SA, Gowravaram M, Basarab GS, Mueller JP. 2013. Benzisoxazoles: in vitro activity of new bacterial DNA gyrase/topoisomerase IV inhibitors against Grampositive, fastidious Gram-negative, atypical, and anaerobic bacterial isolates, poster F-1220. Abstr. 53rd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
24. Collin F, Karkare S, Maxwell A. 2011. Exploiting bacterial DNA gyrase as a drug target: current state and perspectives. Appl. Microbiol. Biotechnol. 92:479-497. http://dx.doi.org/10.1007/s00253-011-3557-z.
25. Mayer C, Janin YL. 2014. Non-quinolone inhibitors of bacterial type IIA topoisomerases: a feat of bioisosterism. Chem. Rev. 114:2313-2342. http://dx.doi.org/10.1021/cr4003984.
26. Tomasic T, Masic LP. 2014. Prospects for developing new antibacterials targeting bacterial type IIA topoisomerases. Curr. Top. Med. Chem. 14: 130-151. http://dx.doi.org/10.2174/1568026613666131113153251.
27. Grossman TH, Bartels DJ, Mullin S, Gross CH, Parsons JD, Liao Y, Grillot AL, Stamos D, Olson ER, Charifson PS, Mani N. 2007. Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds. Antimicrob. Agents Chemotherapy. 51:657-666. http://dx.doi.org/10.1128/AAC.00596-06. (Pubitemid 46185287)
28. Alm RA, Kutschke A, Otterson LG, Lahiri SD, McLaughlin RE, Lewis LA, Su X, Huband MD, Mueller JP, Gardner H. 2013. Novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae (NG) and Staphylococcus aureus (SA), poster F-1225c. Abstr. 53rd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
29. Unemo M, Fasth O, Fredlund H, Limnios A, Tapsall JW. 2009. Phenotypic and genetic characterization of the 2008WHO Neisseria gonorrhoeae reference strain panel intended for global quality assurance and quality control of gonococcal antimicrobial resistance surveillance for public health purposes. J. Antimicrob. Chemother. 63:1142-1151. http://dx.doi.org/10.1093/jac/dkp098.
30. Clinical and Laboratory Standards Institute. 2014 Performance standards for antimicrobial susceptibility testing; 24th informational supplement. CLSI document M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA. http://clsi.org/blog/2014/01/27/m100-s24-em100-2014/.
31. Huband MD, Flamm RK, Rhomberg R, Mueller JP, Jones RN. 2013. In vitro activity of AZD0914: a new benzisoxazole DNA gyrase inhibitor against Neisseria gonorrhoeae, poster F-1225b. Abstr. 53rd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
32. Centers for Disease Control and Prevention. 2012. Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb. Mortal. Wkly. Rep. 61:590-594.
33. Bignell C, Unemo M, European Guidelines Editorial Board STI. 2013. 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults. Int. J. STD AIDS 24: 85-92. http://dx.doi.org/10.1177/0956462412472837.
34. European Committee for Antimicrobial Susceptibility Testing. 2014. Breakpoint tables for interpretation of MICs and zone diameters. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST-files/Breakpoint-tables/ Breakpoint-table-v-4.0.pdf.